BAMS
Bellevue Asset Management (Switzerland) Portfolio holdings
AUM
$656M
This Quarter Return
+10.91%
1 Year Return
+11.48%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$656M
AUM Growth
+$656M
(+7%)
Cap. Flow
-$2.4M
Cap. Flow
% of AUM
-0.37%
Top 10 Holdings %
Top 10 Hldgs %
31%
Holding
140
New
7
Increased
41
Reduced
25
Closed
13
Top Buys
| 1 |
Cardinal Health
CAH
|
$8.17M |
| 2 |
Centene
CNC
|
$5.64M |
| 3 |
Viatris
VTRS
|
$4.88M |
| 4 |
Eagle Bancorp
EGBN
|
$4.88M |
| 5 |
LCI
Lannett Company, Inc.
LCI
|
$4.31M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$13.6M |
| 2 |
Dr. Reddy's Laboratories
RDY
|
$8.31M |
| 3 |
KITE
Kite Pharma, Inc.
KITE
|
$6.5M |
| 4 |
Abbott
ABT
|
$3.66M |
| 5 |
Tenet Healthcare
THC
|
$3.53M |
Sector Composition
| 1 | Healthcare | 93.1% |
| 2 | Financials | 1.62% |
| 3 | Industrials | 0.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $26M | 3.97% | 217,410 -12,350 | -5% | -$1.48M |
|
2
Biogen
BIIB
$19.4B
| $25.7M | 3.92% | 84,030 +12,260 | +17% | +$3.76M |
|
3
Gilead Sciences
GILD
$140B
| $24.3M | 3.7% | 240,120 -13,930 | -5% | -$1.41M |
|
4
Amgen
AMGN
$155B
| $20M | 3.04% | 123,000 +3,000 | +3% | +$487K |
|
5
Regeneron Pharmaceuticals
REGN
$61.5B
| $19.8M | 3.01% | 36,400 -2,500 | -6% | -$1.36M |
|
6
Medtronic
MDT
$119B
| $19.7M | 3.01% | 256,500 -13,500 | -5% | -$1.04M |
|
7
Illumina
ILMN
$15.8B
| $17.5M | 2.67% | 91,425 +3,800 | +4% | +$729K |
|
|
8
Abbott
ABT
$231B
| $17.1M | 2.61% | 381,500 -81,500 | -18% | -$3.66M |
|
|
9
Viatris
VTRS
$12.3B
| $17M | 2.6% | 315,300 +90,300 | +40% | +$4.88M |
|
10
Becton Dickinson
BDX
$55.3B
| $16.2M | 2.47% | 105,075 +12,770 | +14% | +$1.97M |
|
|
11
Cardinal Health
CAH
$35.5B
| $15.3M | 2.33% | 171,480 +91,480 | +114% | +$8.17M |
|
12
UnitedHealth
UNH
$281B
| $14.1M | 2.15% | 120,000 | – | – |
|
13
Stryker
SYK
$150B
| $13.1M | 1.99% | 140,700 | – | – |
|
14
Teva Pharmaceuticals
TEVA
$21.1B
| $11.6M | 1.77% | 176,720 +7,500 | +4% | +$492K |
|
|
ESRX
15
DELISTED
Express Scripts Holding Company
ESRX
| $10.8M | 1.65% | 124,000 -36,000 | -23% | -$3.15M |
|
|
ENDP
16
DELISTED
Endo International plc
ENDP
| $10.5M | 1.6% | 171,000 +13,000 | +8% | +$796K |
|
|
CYTO
17
DELISTED
Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda)
CYTO
| $10.4M | 1.59% | 2,169,625 | – | – |
|
18
Zimmer Biomet
ZBH
$21B
| $9.8M | 1.49% | 95,500 | – | – |
|
|
ALXN
19
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $9.42M | 1.44% | 49,400 | – | – |
|
20
CVS Health
CVS
$92.8B
| $9.41M | 1.43% | 96,200 +41,200 | +75% | +$4.03M |
|
21
Ligand Pharmaceuticals
LGND
$3.15B
| $8.85M | 1.35% | 81,640 -14,090 | -15% | -$1.53M |
|
22
Incyte
INCY
$16.5B
| $8.57M | 1.31% | 79,000 +2,000 | +3% | +$217K |
|
23
Ionis Pharmaceuticals
IONS
$6.79B
| $8.55M | 1.3% | 138,000 +6,000 | +5% | +$372K |
|
24
Boston Scientific
BSX
$156B
| $8.48M | 1.29% | 460,000 +60,000 | +15% | +$1.11M |
|
25
McKesson
MCK
$85.4B
| $8.48M | 1.29% | 43,000 +2,000 | +5% | +$394K |
|